Medication adherence after AMI is poor, some of which may be due to affordability. This trial randomized post-MI patients to full or usual prescription coverage of ACE (or ARB), beta blocker, and statin. Full coverage resulted in ~5% higher adherence to meds, but all groups adherence was <50%. Although there was no difference in the primary outcome between the groups (major vascular event or revascularization), but there was a small reduction in the rate of all vascular events. Although medication affordability plays a role in adherence, rates of adherence are still very low despite full coverage (abstract)
Share This Post
Categories
Related Posts
While all of us see patients who smoke in their 70s or 80s, due to their limited lifespan from COPD, DM, malignancy, etc., and their expressed wishes to continue tobacco, we keep our admonitions to a minimum. We accept our patient has become learned enough through life to make their own decisions and accept whatever […]
Do you have a stack of journals piling up on your desk, beside your bed or in your email inbox? In 1950, medical knowledge was estimated to double every 50 years, but now the doubling time is every few months. At this rate, it is impossible to keep up with the literature, but a group […]
Fill in the Blanks: Q: “The diagnosis of type 2 MI is associated with a _____ prognosis. ___% of patients will live five years after their diagnosis.” The answer is a) POOR and b) a staggering 40%. I did not know that. However, what I am aware of is the ambiguity around Type 2 MIs and […]
Leave A Comment